Source: EURLEX
Language: en
Format: md

|  |  |  |
| --- | --- | --- |
| European flag | Official Journal  of the European Union | EN  Series C |

---

|  |  |  |
| --- | --- | --- |
|  | C/2023/1139 | 4.12.2023 |

Judgment of the General Court of 18 October 2023 — Teva Pharmaceutical Industries and Cephalon v Commission

(Case T-74/21) [(1)](#ntr1-C_202301139EN.000101-E0001)

(Competition - Agreements, decisions and concerted practices - Modafinil market - Decision finding an infringement of Article 101 TFEU - Patent dispute settlement agreement - Restriction of competition by object - Characterisation - Restriction of competition by effect - Conditions for exemption under Article 101(3) TFEU - Fines)

(C/2023/1139)

Language of the case: English

Parties

Applicants: Teva Pharmaceutical Industries Ltd (Petah Tikva, Israel) and Cephalon Inc. (West Chester, Pennsylvania, United States) (represented by: D. Tayar, S. Ortoli and A. Richard, lawyers)

Defendant: European Commission (represented by: G. Conte, T. Franchoo and C. Sjödin, acting as Agents)

Re:

By their action under Article 263 TFEU, the applicants seek annulment of Decision C(2020) 8153 final of the European Commission of 26 November 2020 relating to a proceeding under Article 101 TFEU and Article 53 of the EEA Agreement (Case AT.39686-CEPHALON) and, in the alternative, the cancellation or reduction of the fines.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Teva Pharmaceutical Industries Ltd and Cephalon Inc. to pay the costs. |

---

---

ELI: http://data.europa.eu/eli/C/2023/1139/oj

ISSN 1977-091X (electronic edition)

---

[Top](#document1)